Navigation Links
Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
Date:2/24/2011

esults may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of go
'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
2. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
5. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
6. Jazz Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference in New York on March 1
7. Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant
8. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
9. Onyx Pharmaceuticals Reports Full Year and Fourth Quarter 2010 Financial Results
10. Avanir Pharmaceuticals to Present at Three Conferences in March
11. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... and Markets ( http://www.researchandmarkets.com/research/5hkm2f/medical_oxygen ) has announced ... Global Strategic Business Report" report to their offering. ... Medical Oxygen Systems in US$ Thousands by the following ... Regulators, and Oxygen Conserving Devices. The report provides separate ... , Japan , Europe ...
(Date:4/17/2015)... DULLES, Va. , April 17, 2015 ... and distribution of radiopharmaceuticals, announced today that it has ... IBA Molecular North America, Inc. (IBAM NA), to Illinois Health ... continue to operate as an independent company headquartered in ... well positioned to take advantage of new product and ...
(Date:4/17/2015)... TWi Pharmaceuticals, Inc. ("TWi", Stock Ticker:4180.TT) today ... USA , has obtained state sales licenses from ... been in close contact with the major nationwide retail ... own label specialty generic products sold through these nationwide ... According to IMS Health, the U.S. pharma ...
Breaking Medicine Technology:Medical Oxygen Systems - 2015 Global Strategic Business Report Featuring Leading Players, Caire, Invacare & Philips Respironics 2Health Care System to Acquire IBA Molecular North America 2Health Care System to Acquire IBA Molecular North America 3
... of Bavituximab in ... Carboplatin and Paclitaxel-, TUSTIN, Calif., Jan. 22 ... biopharmaceutical,company developing monoclonal antibodies for the treatment of cancer ... Phase II,clinical protocol to study bavituximab in combination with ...
... II Investigational Trial Published in CANCER: the Journal of the ... ... Cell Therapeutics, Inc.,(CTI) (Nasdaq: CTIC ; MTAX) announced ... the journal CANCER demonstrate that the,addition of radioimmunotherapy (RIT) to ...
Cached Medicine Technology:Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 2Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 3Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 4Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent 2Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent 3Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent 4Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent 5
(Date:4/18/2015)... April 18, 2015 On April 14th, 2015, ... Report , which they say, “exposes a tactical shift by ... malware variants were introduced in 2014 - almost a million ... Day threats to be identified and patched by prominent manufacturers ... clear that doing business in a digital world can be ...
(Date:4/18/2015)... 18, 2015 “ ArcAngel ” was featured ... a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... safety app. , In a turbulent world, people may ... 911 should always be their first move, but some situations ...
(Date:4/18/2015)... French physician and gastronome Anthelme Brillat-Savarin understood the ... “Tell me what you eat, and I will tell ... stress or sadness has often been attributed to women, ... collected from their Emotional Eating Test reveals ... for different reasons. , Collecting data from 521 emotional ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 John Evans, ... Party on the Patio from 2 p.m. to 3 ... located at 1320 Executive Ct. in Pekin, Illinois, serves ... who need some help to maintain their independence. , ... and tropical treats will be served during the luau. ...
(Date:4/17/2015)... April 17, 2015 ERGO-Pedic Products, LLC, ... introducing two new products to help a broader range ... pain relief are the second most common visitors to ... product, designed specifically to help relieve sitting pain. Then, ... and thousands of happy customers later, we began getting ...
Breaking Medicine News(10 mins):Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2
... with 21 pens of cattle in commercial feedlots ... Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian ... a large-scale commercial beef feedlot study with the ... have been published in this month,s issue of ...
... Tens of Thousands of Americans Die Unnecessarily Every Year From Preventable ... ... 13, 2009 -- In support of National Patient Safety Awareness ... and compliance solutions for the healthcare industry, has produced an educational ...
... Cirangle, the most experienced bariatric surgeon in the state of Hawaii is ... the outer islands, Dr. Cirangle,s weight loss surgery patients will now have ... ... (PRWEB) March 13, 2009 -- As America,s fight with obesity continues, it ...
... Center for Refugee Health and Human Rights (BCRHHR) ... the large number of Tibetan refugee monks who ... Boston suffering from symptoms of traumatic stress, interfering ... by their traditional healers as having srog-rLung, a ...
... severely limit the movement of your pet, especially in the winter. ... industry in supplying the best medications to treat arthritis and joint pain ... ... leading online veterinary pharmacy and supplier of pet meds , announced ...
... National Association of Boards of Pharmacy(R) (NABP(R)) is one ... of Excellence in the first round of the 2009 ... sponsored by the American Society of Association Executives (ASAE) ... in Mount Prospect, IL, received the award for its ...
Cached Medicine News:Health News:Econiche(TM) Vaccine Shows 92% Reduction in Colonization of E. coli O157 in Vaccinated Cattle 2Health News:Econiche(TM) Vaccine Shows 92% Reduction in Colonization of E. coli O157 in Vaccinated Cattle 3Health News:Econiche(TM) Vaccine Shows 92% Reduction in Colonization of E. coli O157 in Vaccinated Cattle 4Health News:Econiche(TM) Vaccine Shows 92% Reduction in Colonization of E. coli O157 in Vaccinated Cattle 5Health News:Econiche(TM) Vaccine Shows 92% Reduction in Colonization of E. coli O157 in Vaccinated Cattle 6Health News:Quantros Produces Video Detailing Enormous Problem of Preventable Medical Errors Plaguing The U.S. Healthcare System 2Health News:Quantros Produces Video Detailing Enormous Problem of Preventable Medical Errors Plaguing The U.S. Healthcare System 3Health News:Hawaii's Most Experienced and Only Fellowship-Trained Weight Loss Surgeon Now Coming to Hilo 2Health News:Hawaii's Most Experienced and Only Fellowship-Trained Weight Loss Surgeon Now Coming to Hilo 3Health News:Researchers discover ways of integrating treatment of traumatized Tibetan refugee monks 2Health News:Researchers discover ways of integrating treatment of traumatized Tibetan refugee monks 3Health News:PetCareRx Reinforces its Range of Arthritis and Joint Care Products for Winter 2Health News:NABP Wins ASAE's 2009 Associations Advance America Award of Excellence 2Health News:NABP Wins ASAE's 2009 Associations Advance America Award of Excellence 3
... is a handheld, noninvasive ultrasound instrument that ... operate, so any staff member can scan ... images from exams and print BVI 6100 ... just log on to ScanPoint®, Diagnostic Ultrasound's ...
... The Mobile BladderScan® BVI 6400 calculates ... ultrasound technology. V-MODE® ultrasound is accurate, ... seconds, the BladderScan® measures ultrasonic reflections ... planes, creates a 3-dimensional image of ...
... EXP Injectable Bulking Agent is ... suspended in a water-based carrier ... Agent is indicated for the ... stress urinary incontinence due to ...
... The MIS is designed to ... in the area of the mid-urethra. ... 30 minutes, and can be performed ... department which allows the patient to ...
Medicine Products: